The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology

References

• Diehl V, Mauch PM, Harris NL. Hodgkin’s disease. In: Cancer Principles and Practice of Oncology (6th Edition). DeVita VT, Hellmann S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA, 2339–2387 (2001).
   Google Scholar
• Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J. Nucl. Med.50, 21S–30S (2009).
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol.27, 4548–4554 (2009).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J. Clin. Oncol.25, 3746–3752 (2007).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M et al. FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood107, 52–59 (2006).
   PubMed Web of Science ®Google Scholar
• Markova J, Kobe C, Skopalova M et al. FDG-PET for assessment of early treatment response after 4 cycles of chemotherapy in patients with advanced-stage Hodgkin lymphoma has a high negative predictive value. Ann. Oncol.20, 1270–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Picardi M, De Renzo A, Pane F et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with postchemotherapy negative positron emission tomography scans. Leuk. Lymphoma48, 1721–1727 (2007).
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood112, 3389–3994 (2008).
   Google Scholar
• Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood109, 905–909 (2007).
   PubMed Web of Science ®Google Scholar
• Naumann R, Beuthien-Baumann B, Reiss A et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br. J. Cancer90, 620–625 (2004).
   PubMed Web of Science ®Google Scholar
• Rigacci L, Vitolo U, Nassi L et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann. Hematol.86, 897–903 (2007).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica91, 482–489 (2006).
   PubMed Web of Science ®Google Scholar
• Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J. Nucl. Med.46, 958–963 (2005).
   PubMed Web of Science ®Google Scholar
• Moulin-Romsee G, Hindié E, Cuenca X et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur. J. Nucl. Med. Mol. Imaging37, 1095–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M et al. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur. J. Haematol.78, 206–212 (2007).
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol.25, 571–578 (2007).
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk. Lymphoma17, 1–4 (2009).
   Google Scholar
• Boellaard R, O’Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging37, 181–200 (2010).
   PubMed Web of Science ®Google Scholar
• Furth C, Steffen IG, Amthauer H et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J. Clin. Oncol.27, 4385–4391 (2009).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann. Oncol.17, 1296–1300 (2006).
   PubMed Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Levi I et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann. Oncol.21, 126–132 (2010).
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Mauz-Korholz C et al. FDG-PET in Hodgkin lymphoma. Nuklearmedizin47, 235–238 (2008).
   PubMedGoogle Scholar
• Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med.19, 2500–2507 (2003).
   Google Scholar
• Jacene HA, Leboulleux S, Baba S et al. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J. Nucl. Med.50, 1760–1769 (2009).
   PubMed Web of Science ®Google Scholar
• de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann. Oncol.12, 29–37 (2001).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dont P et al. Can positron emission tomography with [(18F)]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br. J. Haematol.115, 272–278 (2001).
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin’s disease. Blood98, 2930–2934 (2001).
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann. Oncol.14, 123–130 (2003).
   PubMed Web of Science ®Google Scholar
• Mocikova H, Obrtlikova P, Vackova B, Trneny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann. Oncol.21(6), 1222–1227 (2009).
   PubMedGoogle Scholar
• Zinzani PL, Stefoni V, Tani M et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J. Clin. Oncol.27, 1781–1787 (2009).
   PubMed Web of Science ®Google Scholar
• Girinsky T, Ghalibafian M, Bonniaud G et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementaion of the involved-node radiotherapy concept and dose painting? Radiother. Oncol.85, 178–186 (2007).
   PubMed Web of Science ®Google Scholar
• Dühmke E, Franklin J, Pfreundschuh M et al. Low-dose radiation is sufficient for the noninvolved extended field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J. Clin. Oncol.19, 2905–2914 (2001).
   PubMedGoogle Scholar
• Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J. Clin. Oncol.25, 3495–3502 (2007).
   PubMed Web of Science ®Google Scholar
• Engert A, Plütschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N. Engl. J. Med.363, 640–652 (2010).
   PubMed Web of Science ®Google Scholar
• Eich HT, Staar S, Gossmann A et al. Centralized radiation oncological review of cross-sectional imaging of Hodgkin’s disease leads to significant changes of the required involved field – results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys.58, 1120–1126 (2004).
   Google Scholar
• Girinsky T, van der Maazen R, Specht L. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother. Oncol.79, 270–277 (2006).
   PubMed Web of Science ®Google Scholar
• Eich HT, Müller RP, Engenhart-Cabillic R et al. Involved-node raiotherapy in early-stage Hodgkin’s lymphoma: definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther. Onkol.184, 406–410 (2008).
   PubMedGoogle Scholar
• Shahidi M, Kamangari N, Ashley S et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother. Oncol.78, 1–5 (2006).
   PubMed Web of Science ®Google Scholar